H&S Hightech Corp. (XKON:044990)
South Korea · Delayed Price · Currency is KRW 14,850
-120 (-0.80%)
At close: Aug 1, 2025, 3:30 PM KST
Verve Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
Operating Revenue | 78,520 | 76,161 | 80,552 | 45,513 | 52,725 | 28,200 |
Other Revenue | - | - | -0 | -0 | -0 | 0 |
| 78,520 | 76,161 | 80,552 | 45,513 | 52,725 | 28,200 | |
Revenue Growth (YoY) | 48.92% | -5.45% | 76.98% | -13.68% | 86.97% | - |
Cost of Revenue | 43,067 | 42,215 | 45,266 | 25,600 | 27,526 | 12,779 |
Gross Profit | 35,453 | 33,945 | 35,286 | 19,913 | 25,199 | 15,421 |
Selling, General & Admin | 14,609 | 14,802 | 13,621 | 9,040 | 8,343 | 5,427 |
Research & Development | 4,459 | 4,223 | 6,423 | 3,520 | 2,741 | 1,747 |
Operating Expenses | 20,710 | 20,575 | 21,330 | 13,680 | 11,720 | 7,273 |
Operating Income | 14,742 | 13,370 | 13,956 | 6,233 | 13,479 | 8,148 |
Interest Expense | -23.71 | -20.58 | -218.06 | -196.49 | -541.43 | -455.25 |
Interest & Investment Income | 1,447 | 1,373 | 851.1 | 138.23 | 165.61 | 134.24 |
Earnings From Equity Investments | -1,918 | -2,093 | -1,251 | 5.07 | 11.5 | -35.42 |
Currency Exchange Gain (Loss) | 1,418 | 2,390 | 381.93 | 162.56 | -203.24 | -276.09 |
Other Non Operating Income (Expenses) | 304.61 | 330.98 | 20,445 | 187.71 | 67.95 | -94.24 |
EBT Excluding Unusual Items | 15,970 | 15,351 | 34,166 | 6,530 | 12,979 | 7,422 |
Gain (Loss) on Sale of Investments | -25.65 | 893.69 | -6.77 | - | -26 | 4.44 |
Gain (Loss) on Sale of Assets | 1.87 | 1.87 | 131.08 | -12.16 | -5.31 | -4.22 |
Asset Writedown | - | - | - | -2,543 | -2,351 | - |
Other Unusual Items | - | - | - | - | - | 27.68 |
Pretax Income | 15,946 | 16,246 | 34,290 | 3,974 | 10,597 | 7,450 |
Income Tax Expense | 1,451 | 1,579 | 4,151 | 392.61 | -158.92 | 841.82 |
Net Income | 14,495 | 14,667 | 30,139 | 3,581 | 10,756 | 6,608 |
Net Income to Common | 14,495 | 14,667 | 30,139 | 3,581 | 10,756 | 6,608 |
Net Income Growth | 34.76% | -51.33% | 741.53% | -66.70% | 62.78% | - |
Shares Outstanding (Basic) | 8 | 8 | 8 | 7 | 7 | 6 |
Shares Outstanding (Diluted) | 8 | 8 | 8 | 7 | 7 | 7 |
Shares Change (YoY) | 11.61% | 1.01% | 5.37% | 4.59% | -6.66% | - |
EPS (Basic) | 1907.82 | 1935.45 | 4017.12 | 505.00 | 1609.00 | 1136.00 |
EPS (Diluted) | 1907.38 | 1935.00 | 4017.00 | 503.00 | 1580.00 | 906.00 |
EPS Growth | 20.72% | -51.83% | 698.61% | -68.16% | 74.39% | - |
Free Cash Flow | 9,797 | 12,749 | 17,181 | 11,118 | 10,920 | 4,171 |
Free Cash Flow Per Share | 1289.43 | 1682.31 | 2290.04 | 1561.55 | 1604.05 | 571.87 |
Dividend Per Share | 250.000 | 250.000 | 200.000 | - | - | - |
Dividend Growth | - | 25.00% | - | - | - | - |
Gross Margin | 45.15% | 44.57% | 43.81% | 43.75% | 47.79% | 54.68% |
Operating Margin | 18.77% | 17.55% | 17.33% | 13.69% | 25.56% | 28.89% |
Profit Margin | 18.46% | 19.26% | 37.42% | 7.87% | 20.40% | 23.43% |
Free Cash Flow Margin | 12.48% | 16.74% | 21.33% | 24.43% | 20.71% | 14.79% |
EBITDA | 19,867 | 18,304 | 17,638 | 9,529 | 15,223 | 9,337 |
EBITDA Margin | 25.30% | 24.03% | 21.90% | 20.94% | 28.87% | 33.11% |
D&A For EBITDA | 5,124 | 4,934 | 3,682 | 3,296 | 1,744 | 1,189 |
EBIT | 14,742 | 13,370 | 13,956 | 6,233 | 13,479 | 8,148 |
EBIT Margin | 18.77% | 17.55% | 17.33% | 13.69% | 25.56% | 28.89% |
Effective Tax Rate | 9.10% | 9.72% | 12.11% | 9.88% | - | 11.30% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.